Home › Research › Tau biomarkers
Improving the Bioavailability and Efficacy of Coenzyme Q10 on Alzheimer's Disease Through the Arginine Based Proniosomes
Ergin AD, Üner B, Balcı Ş, Demirbağ Ç, Benetti C, Oltulu Ç.. Journal of pharmaceutical sciences, 2023-07-26
Topic: Amyloid, tau and blood-test diagnosis
Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-with a benzoquinone-like structure. CoQ10 plays a role in membrane stability, energy conversion, and ATP production. It is also one of the important antioxidants in the body.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ergin, A. D., Üner, B., Ş, B., Ç, D., Benetti, C., & Ç, O. (2023). Improving the Bioavailability and Efficacy of Coenzyme Q10 on Alzheimer's Disease Through the Arginine Based Proniosomes. Journal of pharmaceutical sciences. https://doi.org/10.1016/j.xphs.2023.07.020
Vancouver
Ergin AD, Üner B, Ş B, Ç D, Benetti C, Ç O. Improving the Bioavailability and Efficacy of Coenzyme Q10 on Alzheimer's Disease Through the Arginine Based Proniosomes. Journal of pharmaceutical sciences. 2023. doi:10.1016/j.xphs.2023.07.020. PMID: 37506768.
BibTeX
@article{ergin2023-37506768,
author = {Ergin, A. D. and Üner, B. and Ş, Balcı and Ç, Demirbağ and Benetti, C. and Ç, Oltulu},
title = {{Improving the Bioavailability and Efficacy of Coenzyme Q10 on Alzheimer's Disease Through the Arginine Based Proniosomes}},
journal = {Journal of pharmaceutical sciences},
year = {2023},
doi = {10.1016/j.xphs.2023.07.020},
pmid = {37506768},
url = {https://doi.org/10.1016/j.xphs.2023.07.020}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- CoQ10 plays a role in membrane stability, energy conversion, and ATP production.
- It is also one of the important antioxidants in the body.
- The bioavailability of exogenous CoQ10 is extremely low due to its poor aqueous solubility and large molecular mass.
- In this study, mixed proniosomal drug delivery systems have been used to increase solubility and bioavailability of CoQ10.
Why it matters
This work used a proniosomal drug delivery system to try to improve the solubility and bioavailability of coenzyme Q10, an antioxidant. It is early laboratory formulation work and does not show that coenzyme Q10 treats, cures or prevents Alzheimer's disease in people.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size0.30%; 90.55%
- Evidence strengthLow
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of pharmaceutical sciences) |
| Journal's citation record | 3 / 4 | Journal of Pharmaceutical Sciences: journal h-index 278 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.4 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 1 / 6 | Cited 0.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Çağatay Oltulu: h-index 8 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | National University of Singapore: institution h-index 1,166 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37506768) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers
Also tagged “precursor”
1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.